Medical/Pharmaceuticals

Aiming for Global CDMO, Xcell Therapeutics opens an export route to 62 countries with cell therapy culture technology.

SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In a hair follicle, there are "dermal follicle papilla cells" that appear 3,000 grapes clustered together. The name was given because its outline resembles the papilla of the human body when observed under a microscope. Hair loss occurs when der...

2021-10-28 21:00 1786

Osfirm to Launch Novel Implantable Biomaterial Whitlockite with Excellent Biodegradability and Bone Regenerative and Reconstructive Properties into Global Market by the Year 2023

SEOUL, South Korea, Oct. 28, 2021 /PRNewswire/ -- In 1941, "whitlockite," the second most abundant inorganic mineral of the bone was named in honor of Herbert Whitlockite, Curator of Minerals and Gems in the American Museum of Natural History inNew York. Whitlockite is a unique form of magnesium ...

2021-10-28 21:00 1785

Merck Drives New Innovation & Adds Capacity to Advance Next Generation Antibody-drug Conjugate (ADC) Therapies

- Merck's unique technology, ChetoSensar™, gives new promise to ADCs by alleviating solubility challenges  - New DOLCORE™ platform increases speed-to-market by up to a year - Expanded ADC clinical manufacturing facility drives next generation ADCs, building on company's 15 years of ADC Contract...

2021-10-28 21:00 4038

HanAll Biopharma Reports Third Quarter 2021 Results

* Q3'21 sales of KRW 25.5 billion increased 15% from the same period last year * Q3'21 operating profit of KRW 2.2 billion grew by 120% compared to Q3'20 * Nine months sales of KRW 76.7 billion and operating profit of KRW 9.2 billion rose by 15% and 67% YoY, repectively SEOUL, South Korea, Oct...

2021-10-28 21:00 2627

BioVaxys Further Expands Intellectual Property Portfolio in Global Markets

- Files Applications for International Patent and Trademark Protection of CoviDTH VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has broadened the patent coverage on CoviDTH, its T ...

2021-10-28 20:00 3844

Interim report for Q3 2021 : Bactiguard Holding AB (publ)

STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Capital injection initiates a new phase of accelerated expansion Third quarter (July-September 2021) * Revenues amounted to SEK 45.2 (34.1) million, an increase of 32%. Adjusted for currency effects revenues increased by 36%. * EBITDA amounted to SEK ...

2021-10-28 15:23 2332

Mentice publishes the company's interim report for the period January-September 2021

STOCKHOLM, Oct. 28, 2021 /PRNewswire/ -- Third quarter (July–September 2021) and the first nine months of the year (January-September 2021) * Order intake amounted to 51.8 (34.6) MSEK for the third quarter and 131.9 (95.5) MSEK for the first nine months of the year. * Order book by the end ...

2021-10-28 15:07 1942

WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility

- Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspections since the start of 2021 WUXI, China, Oct. 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced th...

2021-10-28 08:30 2556

Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China

SAN FRANCISCO and SUZHOU, China, Oct. 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseas...

2021-10-28 08:00 3890

Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults

– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison – DUBLIN and LAKEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Mallinckrodt plc  (OTCMKTS: MNKKQ), a global ...

2021-10-28 05:48 2731

Ingersoll Rand and its Brands Support the Public Health in the Post-Pandemic Era

SINGAPORE, Oct. 27, 2021 /PRNewswire/ -- Ingersoll Rand Inc. (NYSE:IR), a global provider of mission-critical flow creation and industrial solutions, is providing compressed air and vacuum, material handling, and metering solutions to the medical and pharmaceutical industries. Its cutting-edge co...

2021-10-28 05:47 4096

New Wellbeing Trends Report 2030 Reveals Decade-long Impact of Pandemic Upheaval

SYDNEYOct. 28, 2021 /PRNewswire/ -- Jeunesse Global today shared the inaugural Wellness & Aesthetics Trends Report 2030, presenting key macro and micro trends that are set to influence the future of the wellbeing and beauty sectors, based on the evolution of audience behaviours and cultural shift...

2021-10-28 03:54 2665

Launch of Seegene's STARlet-AIOS: All-in-One System Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing

* A true walk away 'sample to answer' molecular diagnostic system designed for high throughput testing, offering a time-efficient and seamless workflow for clinical laboratories * Utilizes Seegene's patented, cutting-edge high multiplex real-time PCR technologies to provide 'Real' Ct values...

2021-10-27 23:40 2858

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 22:08 1972

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 22:06 1712

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), In A Two Drug Regimen, Proves Safe And Effective For Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 22:03 1858

Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore

- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium - - ADG106 now being evaluated in combinations with three leading anti-PD-1 therapies - SAN DIEG...

2021-10-27 20:52 4492

Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS Patients

LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...

2021-10-27 20:47 1436

Novavax Files for Authorization of its COVID-19 Vaccine in the United Kingdom

* Filing marks first protein-based COVID-19 vaccine submitted to MHRA for authorization * All modules required for regulatory review, including CMC data, are now complete * Submission based on Phase 3 data from ~45K patients demonstrating high efficacy and well-tolerated safety, including a...

2021-10-27 20:30 3998

European Wellness Collaborates with Heidelberg University Germany to Conduct Efficacy Studies of Peptides and Cell Therapy Research

FRANKFURT, Germany, Oct. 27, 2021 /PRNewswire/ – European Wellness Academy (EWA), the educational arm of European Wellness Biomedical Group (EWG), has signed an agreement to carry out joint scientific research on theefficacy of peptides, cell therapy, exosomes and cell reprogramming for rejuvenat...

2021-10-27 18:48 3538
1 ... 611612613614615616617 ... 646